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Introduction: Most studies describing the natural history and prog-
nostic factors for malignant pleural mesothelioma antedate accurate
pathologic diagnosis, staging by computed tomography, and a uni-
versal staging system. We conducted a large single-institution anal-
ysis to identify prognostic factors and assess the association of
resection with outcome in a contemporary patient population.
Methods: Patients with biopsy-proven malignant pleural mesothe-
lioma at our institution were identified and clinical data were
obtained from an institutional database. Survival and prognostic
factors were analyzed by the Kaplan-Meier method, log-rank test,
and Cox proportional hazards analysis. A p value 0.05 was
considered statistically significant.
Results: From 1990 to 2005, 945 patients were identified: 755 men,
190 women; median age, 66 years (range, 26–93). Extrapleural
pneumonectomy was performed in 208 (22%), pleurectomy/decor-
tication in 176 (19%). Operative mortality was 4% (16/384). Mul-
timodality therapy including surgery was associated with a median
survival of 20.1 months. Significant predictors of overall survival
included histology, gender, smoking, asbestos exposure, laterality,
surgical resection by extrapleural pneumonectomy or pleurectomy/
decortication, American Joint Committee on Cancer stage, and
symptoms. A Cox model demonstrated a hazard ratio of 1.4 without
surgical resection when controlling for histology, stage, gender,
asbestos exposure, smoking history, symptoms, and laterality (p 
0.003).
Conclusions: In addition to tumor histology and pathologic stage,
predictors of survival include gender, asbestos exposure, smoking,
symptoms, laterality, and clinical stage. Surgical resection in a
multimodality setting was associated with improved survival.
Key Words: Malignant mesothelioma, Extrapleural pneumonec-
tomy, Pleurectomy, Decortication.
(J Thorac Oncol. 2007;2: 957–965)
The treatment of malignant pleural mesothelioma (MPM)has evolved in the past 20 years. Although controversy
still exists with regard to standard care, significant advances
have been made in diagnosis, imaging, staging, patient selec-
tion, chemotherapy, surgical technique, and radiotherapy.
Before 1990, pathologic diagnosis was less precise. There-
fore, older series included adenocarcinomas and sarcomas
inadvertently diagnosed as epithelioid and sarcomatoid me-
sotheliomas, respectively, leading to inaccurate survival in-
formation. Table 1 shows some of the largest and most
relevant studies in MPM.1–10
Older data, including the surgical series reported by
Butchart et al.,3 used patient chest radiographs as the only
imaging modality because computed tomography (CT) was
not yet universally used until the late 1990s. In addition,
patient selection for surgery was less accurate because car-
diopulmonary function testing was not done as thoroughly as
it is today. Finally, a universally accepted staging system was
not developed until 1995.11 However, the AJCC/UICC
(American Joint Committee on Cancer/Union Internationale
Contre le Cancer) staging system now allows grouping of
similar stage patients into similar survival groups and for
comparisons among different studies.
Current treatment practices are still highly individual-
ized and range from radical resection with extrapleural pneu-
monectomy (EPP) to observation alone. Most surgical series
are retrospective, not contemporary, and lack a nonsurgically
treated comparison group. Only recently have chemothera-
peutic agents such as pemetrexed and cisplatin demonstrated
significant activity in this difficult to manage disease.10 As
chemotherapy developed during this period, the mortality of
surgical resection with EPP decreased from the once prohib-
itive mortality of 31% to less than 5%, therefore, driving a
reevaluation of surgical management, especially in a multi-
modality setting.
Significant improvements in areas of diagnosis, imag-
ing, and treatment led us to undertake this study to identify a
homogeneous group of MPM patients diagnosed by modern
methods and staged according to the AJCC staging system to
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identify accepted prognostic factors, identify new ones, and
evaluate the association of surgical resection with survival.
MATERIALS AND METHODS
After internal review board approval for development
and analysis of this database, patients with biopsy-proven
MPM from 1990 to 2005 at Memorial Sloan-Kettering Can-
cer Center were identified from the Department of Pathology
database. Pathologic diagnosis was based on histology, im-
munohistochemical analysis, and, when indicated, electron
microscopy. Clinical data were obtained from an institutional
database and verified against source documents. Variables
recorded included symptoms, gender, histologic subtype, lat-
erality, stage, smoking history, asbestos exposure history,
surgical procedure, and multimodality treatment. Staging was
performed using the sixth edition of the AJCC staging man-
ual.11 Clinical stage was based on the reported interpretation
of CT findings. Pathologic stage was based on the patholo-
gist’s evaluation of the resected specimen and the surgeon’s
intraoperative findings. All patients were followed until
death or December 31, 2005 if still alive. Dates of death
were verified through the Social Security Death Index.
There were six foreign patients for whom follow-up data
were unavailable.
Treatment Selection and Methods
Treatment selection was based primarily on tumor
stage and the patient’s overall medical condition, but also
influenced by sequential clinical trials performed at Me-
morial Sloan-Kettering Cancer Center. Operative interven-
tion was recommended to patients with tumor localized to
the hemithorax by CT and adequate cardiopulmonary func-
tion by cardiac stress testing and pulmonary function
testing. Routine mediastinoscopy and magnetic resonance
imaging were not performed. Positron emission tomogra-
phy has only recently been used for clinical staging. EPP
was defined as an en bloc resection of the pleura, lung,
ipsilateral diaphragm, and pericardium. Pleurectomy/de-
cortication (P/D), which removed all gross tumor without
removing underlying lung was performed in patients who had
minimal visceral pleural tumor or poor pulmonary function. The
decision to perform an EPP was based on intraoperative findings
of a confluent visceral tumor not separable from the underlying
lung and a partially or totally fused pleural space. The decision
to perform chemotherapy or radiation was based on enroll-
TABLE 1. Time Periods, Numbers of Patients, and Median
Survival in Large Studies of MPM
Study Years No. of Pts. MS (mo)
Ruffie et al.1 1964–1985 332 7
Alberts et al.2 1965–1985 262 10
Butchart et al.3 1959–1972 29 6
Sugarbaker et al.4 1980–1997 183 17
Rusch and Venkatraman5 1983–1998 174 18
Herndon et al.6 1984–1994 337 7
Aziz et al.7 1989–1998 302 9, 14, 35a
Lee et al.8 1995–2000 32 18
Maggi et al.9 1998–2000 32 9.5, NRb
Vogelzang et al.10 1999–2001 456 9, 12c
Current study (Flores et al.) 1990–2005 945 13
MPM, malignant pleural mesothelioma; MS, median survival; NR, not reported.
a Patients with palliative treatment alone had an average survival of 9 months.
Surgery by extrapleural pneumonectomy or pleurectomy/decortication had an average
survival of 13 and 14 months, respectively. Radical surgery followed by postoperative
chemotherapy had survival of 35 months.
b Eight of 27 medium-term survivors died with a medium survival of 9.5 months.
Twenty-one patients are alive with a median follow-up of 12.5 months.
c Nine months for patients receiving cisplatin and 12 months for those receiving
cisplatin and pemetrexed.
TABLE 2. Patient Characteristics of 945 Patients
Median age: 66 yr (range, 26–93)
Men: 755 (80%)
Women: 190 (20%)
Symptoms
Chest pain: 167 (18%)
Dyspnea: 323 (34%)
Cough: 92 (10%)
Asymptomatic: 94 (10%)
Unknown: 269 (29%)
Histology
Epithelioid: 319 (34%)
Mixed: 99 (10%)
Sarcomatoid: 44 (5%)
Unclassified: 483 (51%)
AJCC Stage Pathologic % Clinical %
I 22 2 99 11
II 85 9 173 18
III 227 24 141 15
IV 153 16 54 7
Unknown 458 48 478 49
Treatment %
208 EPP 22
176 P/D 19
174 ET 18
387 Nonoperative 41
Smoking History No. (%)
Current or former smoker 486 (52)
Never smoker 142 (15)
Unknown 317 (33)
Asbestos history
Asbestos exposure 399 (43)
No asbestos exposure 190 (20)
Unknown 356 (37)
Laterality
Right 520 (55)
Left 349 (37)
Bilateral 76 (8)
AJCC, American Joint Committee on Cancer; EPP, extrapleural pneumonectomy;
P/D, pleurectomy/decortication; ET, exploratory thoracotomy.
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ment in a clinical trial. When the patient could not participate
in a clinical trial, treatment was usually administered accord-
ing to protocol guidelines. The total radiation dose and
method of administration were dependent on whether an EPP
or a P/D had been performed.12,13
Statistical Methods
Operative mortality included all patients who died
within 30 days of surgery or during the same hospitalization.
Survival was calculated from the date of the initial diagnostic
biopsy until date of death or date of last follow-up. Survival
and prognostic factors were analyzed by the Kaplan-Meier
method, and the log-rank test was used to assess statistical
significance. A Cox proportional hazard analysis was used to
assess the joint influences of predictors on survival. Missing
variables were handled as separate groups. The initial
model was performed including significant predictors of
survival from Table 2. Insignificant variables were then
dropped using a stepwise procedure, thus yielding the final
model. A p value of 0.05 was considered statistically
significant. The statistical package used was the R Devel-
opment Core Team (2005, Vienna, Austria).
FIGURE 1. Overall survival by his-
tology (p  0.001).
FIGURE 2. Survival by pathologic
stages I–II versus 3–4 (p  0.001).
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RESULTS
Demographic Information
A total of 945 patients were identified and clinical
features are outlined in Table 2.
Multimodality Therapy with Surgical Resection
Of the 384 patients who had surgical resection, operative
mortality was 11 (5%) for EPP and five (3%) for P/D. Overall
operative mortality was 4% (16/384). Exploratory thoracotomy
(ET) without resection had a zero operative mortality. For patients
who had a macroscopic complete resection by EPP or P/D, the
type of adjuvant or treatment varied according to several clinical
trials performed over this period: surgical resection plus external
beam radiation therapy, induction gemcitabine/cisplatin fol-
lowed by EPP and external beam radiation therapy, induction
pemetrexed/cisplatin followed by EPP and external beam radi-
ation therapy, and several small trials of oral suberoylanilide
hydroxamic acid and 10-propargyl-10-deazaaminopterin.
Of the 384 patients who had either an EPP or P/D, 207
received adjuvant therapy, including 130 who had radiation
without chemotherapy, 35 who had chemotherapy without radi-
ation, and 42 who received both chemotherapy and radiation.
FIGURE 3. Survival by clinical
stages 1–2 versus 3–4 (p  0.01).
FIGURE 4. SURVIVAL BY GENDER
(P < 0.001).
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Therapy without Surgical Resection
A total of 561 patients did not have resection including
174 who underwent thoracotomy but had incomplete tumor
resected at exploration. Of these, 61 received chemotherapy, 12
received palliative external beam radiotherapy, and 101 were
treated with best supportive care.
In the group of 387 patients who did not undergo
surgical exploration, 76 had evidence of stage IV disease,
seven had sarcomatoid tumors, and 304 refused surgery or
were deemed medically inoperable. Of these, 74 received
chemotherapy, 296 had best supportive care, and 17 had no
available treatment data.
Statistical Analysis
Kaplan-Meier survival analysis
Survival data were available for 939 patients and the
median overall survival was 12.5 months. Univariate analysis
showed that epithelioid histology was associated with the best
survival and sarcomatoid with the worst survival (Figure 1).
Tumors of unclassified histology had a survival midway
between the epithelioid and nonepithelioid histologies. There
were 483 patients with unclassified histology due to missing
pathology slides that were unavailable for re-review because
FIGURE 5. Survival by smoking his-
tory (p  0.002).
FIGURE 6. Survival by history of as-
bestos exposure (p  0.001).
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they were from another institution or lost in storage. How-
ever, all patients had slides reviewed at least once at Memo-
rial Sloan-Kettering Cancer Center.
Overall survival for patients with early (I–II) versus late
(III–IV) stage tumors was significantly different (Figure 2).
Although radiographic imaging is known to have limitations
in the staging MPM, patients clinically staged by CT as early
(stages I–II) versus late (stages III–IV) were found to have
significantly different survivals as well (Figure 3). There
were 478 patients with unknown clinical stage. All patients
with available CT scans were staged clinically. We did not
stage patients by chest radiograph alone because the presence
of a pleural effusion could vary from a stage I to a stage IV
and therefore lead to a staging bias.
Female gender, lack of a smoking history, lack of a history
of asbestos exposure, and left-sided tumors were all associated
with a better prognosis (Figures 4–7). The significance of tumor
laterality was not a direct result of operative mortality because
the operative mortality of right- and left-sided tumors was equal.
Patients who presented with chest pain had a significantly worse
median survival (9.4 months) than patients without chest pain
(15 months, p  0.02) (Figure 8).
FIGURE 7. Survival by laterality (p 
0.001).
FIGURE 8. Survival by symptom
presentation (p  0.02).
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Patients who underwent surgical resection had signifi-
cantly better survival than patients without surgical resection
(Figure 9). However, the type of surgical resection (EPP
versus P/D) did not significantly influence survival. The
greatest survival difference was demonstrated in patients who
underwent multimodality therapy with surgery compared
with patients who underwent surgery alone (median survival,
20 versus 10 months) (Figure 10).
Cox Proportional Hazards Model
To minimize selection bias, we controlled for tumor
stage in both the surgical and nonsurgical groups. Other
variables included smoking, asbestos exposure, gender, pain,
histology, and laterality. After all variables were dichoto-
mized, the association of surgical resection with survival
remained statistically significant with a hazard ratio of 0.75
(CI: 62, 91) and a p value of 0.003. (Table 3).
DISCUSSION
Recent advances in the multimodality management of
MPM include more accurate methods of pathologic diagno-
sis, improved physiologic testing leading to better patient
selection for surgery, lower operative mortality, improved
FIGURE 9. Survival by surgical re-
section, extrapleural pneumonectomy
(EPP), and pleurectomy/decortication
(P/D) versus ET (exploratory thoracot-
omy) and nonoperative (p  0.001).
FIGURE 10. Survival by multimo-
dality treatment versus surgical resec-
tion alone (p  0.001). EPP, ex-
trapleural pneumonectomy; P/D,
pleurectomy/decortication.
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local control with combined EPP and hemithoracic radiation,
and better systemic therapies.10,12–14 However, controversy
still exists regarding stratification variables for clinical trials
and the influence of surgical resection on survival. Unlike
studies of more common malignancies that include thousands of
patients, most large MPM studies contain only a few hundred,
making it harder to identify reliable prognostic factors.
The largest and most comprehensive report by Ruffie et
al.1 was a multi-institutional, retrospective study of 332 MPM
patients over a 20-year period. It provided a benchmark
against which many modern studies are compared, although it
lacks the technologic advances available today. Tumor his-
tology and chest pain were identified as significant prognostic
variables. Resection was performed in only 86 patients and
was not associated with improved survival. Operative mor-
tality was 13%.
Since then, operative mortality at high volume centers
has decreased to 5%.4,5 However, recent surgical series do not
provide a perspective of how many patients are candidates for
resection or of the outcome of patients managed nonsurgi-
cally. The methodology for this study was identical to that
used in the Ruffie et al. study with the advantages of a much
larger number of patients treated both surgically and nonsur-
gically and of improved contemporary approaches to diagno-
sis, staging, and treatment selection.
This study confirmed that most patients are male, have
epithelioid tumors, and present with locally advanced disease.
However, contrary to the perception that most patients present
with clinically unresectable disease, more than half of the pa-
tients with MPM at our institution were candidates for resection.
Histology, pathologic stage, and symptoms are con-
firmed as significant predictors of survival and should con-
tinue to be used as stratification variables in clinical trials.
Gender, smoking history, asbestos exposure, and laterality
are significant predictors as well in this large series. These
variables require validation in prospective studies but will
help the design of prospective clinical trials. Based on the
positive prognostic value of female gender in this study,
future prospective studies should attempt to stratify patients
by gender because a preponderance of females in any one
study could result in falsely improved survival rates.
CT is known to be somewhat inaccurate as a method of
clinical staging. However, our results show that CT correctly
stratifies patients by early and late clinical stage disease and
is, therefore, useful for patient stratification in future clinical
trials. In conjunction with positron emission tomography, CT
enables appropriate selection of initial treatment in MPM.15,16
Any retrospective study has limitations. As with the
Ruffie et al. study, missing variables were handled in a
manner to minimize bias. Although confounding variables
were included in the Cox model, unknown confounders may
be present that influence outcome as well. The criticism of
recommending resection based solely on retrospective studies
is the inherent presence of selection bias of the earlier staged
patients and the lead-time bias that may account for the
apparent improved survival. However, to date, no retrospec-
tive study comparing surgically and nonsurgically treated
patients has ever demonstrated a statistically significant dif-
ference in survival between the two groups. Although no
study can prove the benefit of surgery or of multimodality
therapy outside the context of a prospective randomized trial,
our data strongly suggest benefit from multimodality therapy
and underscore the importance of a multidisciplinary team
evaluation before the initiation of treatment. Finally, this
study provides a modern benchmark against which future
studies can be compared, using recent advances in diagnosis,
staging, imaging, and treatment. The prognostic variables
defined here will aid in the design of prospective clinical
trials in MPM.
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